Undisclosed respiratory disease target

The term "Undisclosed respiratory disease target" is a placeholder designation used in the pharmaceutical and biotechnology industries to refer to a specific biological molecule—such as a protein, enzyme, or receptor—that is being targeted by a drug candidate but has not yet been publicly identified. This practice is common during the early stages of drug development, including preclinical research and Phase 1 clinical trials, to protect intellectual property and maintain a competitive advantage, particularly for novel or "first-in-class" mechanisms. For example, companies like GSK and Recursion Pharmaceuticals currently have active programs (e.g., EMP-012 and REC-4209) for respiratory conditions like COPD and IPF where the molecular targets remain undisclosed to the public. Historically, some targets initially labeled as "undisclosed," such as TNIK (Traf2- and Nck-interacting kinase) in Insilico Medicine's idiopathic pulmonary fibrosis program, are eventually revealed as the candidates progress into later-stage clinical trials or upon the publication of peer-reviewed research.